^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 amplification

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1year
    Reed-Sternberg cells (malig cell in Hodgkin) strongly express PDL1 due to amplification of 9p24 which contains the PDL1 & PDL2 locus. An exuberant microenvironment includes plenty of PD1+ T-cells and other immune cells. (fig: Roemer et al, JCO 2018) (@graham74GC)
    Immune cell
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    PD-L1 expression • PD-L1 amplification
    2years
    Newly Dx Extra-hepatic BTC - HER2 amplification is X298CN @Aiims1742 @pashtoonkasi PD-L1 amplificationX12CN @Dr_R_Kurzrock @EthanSokol @KlempnerSam @oncologician @GIcancerDoc Tx suggestions ? Chemo plus Anti- HER+- Pembro? (@UmutDisel)
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 amplification • PD-L1 amplification
    |
    Keytruda (pembrolizumab)
    3years
    In hodgkins where PDL1 amplification is assumed, IO is given without checking for TMB . (@RenoHemonc)
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 amplification
    3years
    Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors | Cancer Biomarkers | JAMA Oncology | JAMA Network https://t.co/GzKrecMzwC (@Dr_R_Kurzrock)
    Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 amplification
    3years
    PD-1 blockades doesn't seem to work in DLBCL [Ansell. JCO. 2019.] Perhaps better patient selection like our solid tumor colleagues? High TMB? PD-L1 expression? PD-L1 amplification? PD-L1 translocations? Anything I am missing @Dr_R_Kurzrock (@AaronGoodman33)
    Clinical • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • TMB-H • PD-L1 amplification
    over3years
    Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors | Cancer Biomarkers | JAMA Oncology | JAMA Network GoodmAn/KurzrockLab https://t.co/GzKrecMzwC (@Dr_R_Kurzrock)
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 amplification
    over3years
    Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer https://t.co/ST4MwkMTHc (@AndresFCardonaZ)
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 amplification
    |
    Opdivo (nivolumab)
    over3years
    Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden - Jco po https://t.co/6n6MY8y5jf (@Dr_R_Kurzrock)
    Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker
    |
    TMB (Tumor Mutational Burden) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    TMB-H • PD-L1 amplification
    over3years
    Congrats to Natalie Reizine @UCHemOncFellows for showcasing a great story! Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1–Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti–PD-1 Monoclonal Antibody Therapy https://t.co/O5MeFh5Xgi (@DocCatenacci)
    Clinical
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR amplification • PD-L1 amplification
    over3years
    Metastatic basal cell carcinoma with high TMB and amplification of PD-L1: exceptional response to anti-PD1 therapy - Liver and brain mets. CR 4+ years. Center for Personalized Cancer Therapy https://t.co/N5Wqf6JLAQ (@Dr_R_Kurzrock)
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 amplification
    almost4years
    The updated ORR and PFS are presented here, noting an increase in ORR. Difference seems amplify with PD-L1 overexpression. Surprising - why should PD-L1 lead to TIGIT working better. I would note that the ORR to atezolizumab alone in this group seems low. #ASCO20 #LCSM (@Jbauml)
    PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 overexpression • PD-L1 amplification
    |
    Tecentriq (atezolizumab)
    almost4years
    Finally a predictive biomarker for IO in breast cancer -A gain/amplification of CD274 . PD-L1 protein is encoded by gene CD274.Exploratory analyses by Thomas Bachelot at #ESMOBreast20 : mOS in chemo arm -8.8 m Vs NR in durvalumab arm @UmutDisel @FAndreMD (@oncologician)
    PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 amplification
    |
    Imfinzi (durvalumab)
    almost4years
    PD-L1 gain/amplification as biomarker for #TNBC selection to IO Few patients, but encouraging OS benefit for patients in durvalumab cohort 👉Efficacy of IO also observed in other tumors 👉Can PD-L1 amplification be an agnostic biomarker for IO? @FAndreMD @myESMO @OncoAlert (@antoniomarraMD)
    Clinical • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 amplification
    |
    Imfinzi (durvalumab)
    almost4years
    The #overallsurvival spread here according to PDL1/CD274 gain/amplification is impressive. I think we can all agree PDL1 testing alone is likely not the ideal bio marker- this should be examined further. #SAFIR02 #ESMOBreast20 @OncoAlert #bcsm (@ErikaHamilton9)
    Clinical • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 amplification